MX2024008530A - Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea. - Google Patents

Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea.

Info

Publication number
MX2024008530A
MX2024008530A MX2024008530A MX2024008530A MX2024008530A MX 2024008530 A MX2024008530 A MX 2024008530A MX 2024008530 A MX2024008530 A MX 2024008530A MX 2024008530 A MX2024008530 A MX 2024008530A MX 2024008530 A MX2024008530 A MX 2024008530A
Authority
MX
Mexico
Prior art keywords
compositions
treatment
methods
eye disease
thyroid eye
Prior art date
Application number
MX2024008530A
Other languages
English (en)
Spanish (es)
Inventor
Vahe Bedian
Yang Zhao
Original Assignee
Viridian Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viridian Therapeutics Inc filed Critical Viridian Therapeutics Inc
Publication of MX2024008530A publication Critical patent/MX2024008530A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024008530A 2022-01-07 2023-01-06 Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea. MX2024008530A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263266548P 2022-01-07 2022-01-07
PCT/US2023/060206 WO2023133485A2 (en) 2022-01-07 2023-01-06 Compositions and methods for treatment of thyroid eye disease

Publications (1)

Publication Number Publication Date
MX2024008530A true MX2024008530A (es) 2024-09-26

Family

ID=87074297

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024008530A MX2024008530A (es) 2022-01-07 2023-01-06 Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea.

Country Status (8)

Country Link
US (1) US20240360227A1 (cg-RX-API-DMAC7.html)
EP (1) EP4460524A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025503339A (cg-RX-API-DMAC7.html)
KR (1) KR20240130134A (cg-RX-API-DMAC7.html)
CN (1) CN118679187A (cg-RX-API-DMAC7.html)
AU (1) AU2023205915A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024008530A (cg-RX-API-DMAC7.html)
WO (1) WO2023133485A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3195512A1 (en) 2020-10-14 2022-04-21 Vahe Bedian Compositions and methods for treatment of thyroid eye disease
JP2024531151A (ja) 2021-08-10 2024-08-29 ビリジアン セラピューティクス, インコーポレイテッド 甲状腺眼疾患の処置のための組成物、用量および方法
CN122003247A (zh) 2023-07-07 2026-05-08 维里迪安治疗公司 治疗活动性和慢性甲状腺眼病的方法
CN121752595A (zh) * 2023-09-08 2026-03-27 北京拓界生物医药科技有限公司 Igf-1r及tshr结合蛋白及其医药用途
AU2024408268A1 (en) * 2023-12-17 2026-07-09 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
WO2026095974A1 (en) 2024-10-30 2026-05-07 Horizon Therapeutics Ireland Dac Methods of treating thyroid eye disease
WO2026128897A1 (en) * 2024-12-15 2026-06-18 Viridian Therapeutics, Inc. Methods for treatment of chronic thyroid eye disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
WO2007062037A2 (en) * 2005-11-21 2007-05-31 Laboratoires Serono Sa Compositions and methods of producing hybrid antigen binding molecules and uses thereof
WO2013169611A1 (en) * 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Compositions and methods for treating breast cancer

Also Published As

Publication number Publication date
JP2025503339A (ja) 2025-02-03
KR20240130134A (ko) 2024-08-28
WO2023133485A3 (en) 2023-08-10
WO2023133485A2 (en) 2023-07-13
AU2023205915A1 (en) 2024-07-18
CN118679187A (zh) 2024-09-20
EP4460524A4 (en) 2026-03-04
EP4460524A2 (en) 2024-11-13
US20240360227A1 (en) 2024-10-31

Similar Documents

Publication Publication Date Title
MX2023004280A (es) Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea.
WO2023133485A3 (en) Compositions and methods for treatment of thyroid eye disease
WO2023133486A3 (en) Compositions and methods for treatment of thyroid eye disease
MY207784A (en) Anti-cd73 antibodies
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2024013016A (es) Anticuerpos anti-pd1 para usarse en el tratamiento del cancer
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
ZA202309516B (en) Anti-ccr8 antibodies
MX2026000030A (es) Métodos de tratamiento de la enfermedad ocular tiroidea crónica
WO2022132596A3 (en) Tissue-specific antigens for cancer immunotherapy
MX2024012567A (es) Composiciones farmaceuticas de anticuerpos biespecificos anti-cd20/anti-cd3 y metodos de uso
MX2023010278A (es) Metodos para el tratamiento de la enfermedad ocular tiroidea.
JOP20210245A1 (ar) طرق لعلاج الداء النشواني من النوع خفيف السلسلة
MX2020011176A (es) Metodos para tratar cancer con una combinacion de un anticuerpo anti-molecula de muerte programada 1 y un conjugado de anticuerpo anti-factor tisular-medicamento.
AU2017310412A8 (en) Method of improving connective tissue attachment using anti-sclerostin antibodies
MX2023005841A (es) Anticuerpos anti-marco y usos de estos.
JOP20220193A1 (ar) صياغات من الأجسام المضادة لـ tslp البشرية وطرق لاستخدامها
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
MX2025005092A (es) Anticuerpo anti-trem2 y usos del mismo
ZA202401405B (en) Compositions and methods for anti-pacap antibodies
JOP20210247A1 (ar) علاج الصداع باستخدام أجسام مضادة لـ cgrp
MX2023012300A (es) Anticuerpos humanos contra artemina y metodos de uso de estos.
WO2021257695A3 (en) Methods and compositions related to neutralizing antibodies against human coronavirus
CA3242672A1 (en) Compositions and methods for treatment of thyroid eye disease
WO2020186111A3 (en) Vista-binding antibodies and uses thereof